Market Exclusive

Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Financial Statements and Exhibits

Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Financial Statements and ExhibitsItem 9.01

Financial Statements and Exhibits.

(d)Exhibits

The exhibit filed as part of this Current Report on Form 8-K is set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

EXHIBIT INDEX

Recro Pharma, Inc. ExhibitEX-99.1 2 d465100dex991.htm EX-99.1 EX-99.1 Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg MALVERN,…To view the full exhibit click here
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Exit mobile version